TY - JOUR
T1 - Integration of genetic counsellors in genomic testing triage: Outcomes of a Genomic Consultation Service in British Columbia, Canada
AU - Cook, Courtney B.
AU - Dragojlovic, Nick
AU - Siemens, Angela
AU - Adam, Shelin
AU - du Souich, Christèle
AU - van Karnebeek, Clara
AU - Lehman, Anna
AU - CAUSES Study
AU - GenCOUNSEL Study
AU - Nelson, Tanya N.
AU - Friedman, Jan
AU - Lynd, Larry D.
AU - Elliott, Alison M.
N1 - Funding Information:
The CAUSES Study was funded by Mining for Miracles (BCCH Foundation) and Genome British Columbia , with support from the Provincial Health Services Authority and BC Women's Hospital . Investigators in the CAUSES Study (Clinical Assessment of the Utility of Sequencing as a Service) include: Shelin Adam, Nick Dragojlovic, Christèle du Souich, Alison M. Elliott, Anna Lehman, Larry Lynd, Jill Mwenifumbo, Tanya N. Nelson, Clara van Karnebeek, and Jan M. Friedman (PI). The bioinformatic pipeline used in part of the CAUSES study was developed in the laboratory of Wyeth Wasserman.
Funding Information:
The GenCOUNSEL Study was funded through the Large Scale Applied Research Project (LSARP) Genome Canada competition with co-funding from: Canadian Institute for Health Research (CIHR) , Genome BC , Genome Quebec , Provincial Health Services Authority , BC Children's Hospital Foundation and BC Women's Hospital Foundation . The GenCOUNSEL Study is led by Alison M. Elliott, Jehannine Austin, Bartha Knoppers, and Larry D. Lynd with Project Manager Alivia Dey, and includes the following co-investigators: Shelin Adam, Nick Bansback, Patricia Birch, Lorne Clarke, Nick Dragojlovic, Jan Friedman, Debby Lambert, Daryl Pullman, Alice Virani, Wyeth Wasserman, and Ma'n Zawati.
Funding Information:
The GenCOUNSEL Study was funded through the Large Scale Applied Research Project (LSARP) Genome Canada competition with co-funding from: Canadian Institute for Health Research (CIHR), Genome BC, Genome Quebec, Provincial Health Services Authority, BC Children's Hospital Foundation and BC Women's Hospital Foundation. The GenCOUNSEL Study is led by Alison M. Elliott, Jehannine Austin, Bartha Knoppers, and Larry D. Lynd with Project Manager Alivia Dey, and includes the following co-investigators: Shelin Adam, Nick Bansback, Patricia Birch, Lorne Clarke, Nick Dragojlovic, Jan Friedman, Debby Lambert, Daryl Pullman, Alice Virani, Wyeth Wasserman, and Ma'n Zawati. The CAUSES Study was funded by Mining for Miracles (BCCH Foundation) and Genome British Columbia, with support from the Provincial Health Services Authority and BC Women's Hospital. Investigators in the CAUSES Study (Clinical Assessment of the Utility of Sequencing as a Service) include: Shelin Adam, Nick Dragojlovic, Christ?le du Souich, Alison M. Elliott, Anna Lehman, Larry Lynd, Jill Mwenifumbo, Tanya N. Nelson, Clara van Karnebeek, and Jan M. Friedman (PI). The bioinformatic pipeline used in part of the CAUSES study was developed in the laboratory of Wyeth Wasserman.
Publisher Copyright:
© 2020 Elsevier Masson SAS
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Purpose: Clinical diagnostic genome-wide (exome or genome) sequencing (GWS) in British Columbia requires funding approval by a provincial agency on a case-by-case basis. The CAUSES Clinic was a pediatric translational trio-based GWS study at BC Children's and Women's Hospitals. Referrals to the CAUSES Clinic were made through a Genomic Consultation Service (GCS), a multidisciplinary team led by genetic counsellors that provided advice regarding genomic testing for physicians considering GWS for their patients. Here we review the outcomes of the GCS, focusing on patients not recommended for the CAUSES Study. Methods: Demographic, clinical, and testing data were abstracted from patient charts. Logistic regression analysis was used to explore associations between demographic and clinical variables and two outcomes: the type of recommendation and referring physicians’ decisions to follow the recommendation. Results: Of 972 GCS referrals, 248 patients were not referred to the CAUSES Study. GWS (vs. a targeted test; e.g. multi-gene panel) was more likely to be recommended to physicians of patients with ID than physicians of patients without ID (OR = 2.98; 95% CI = 1.46 to 6.27; n = 149). In total, 40% of physicians who were recommended to pursue clinical genomic testing submitted an application for funding approval; 71% of applications were approved for funding. Among approved tests, 50% resulted in a diagnosis, including 33% of targeted tests and 82% of GWS tests (χ2 (1) = 5.0, p = 0.026). Conclusion: The GCS provided an effective model in which physicians can interface with genetic specialists, including genetic counsellors, to facilitate appropriate genomic test selection.
AB - Purpose: Clinical diagnostic genome-wide (exome or genome) sequencing (GWS) in British Columbia requires funding approval by a provincial agency on a case-by-case basis. The CAUSES Clinic was a pediatric translational trio-based GWS study at BC Children's and Women's Hospitals. Referrals to the CAUSES Clinic were made through a Genomic Consultation Service (GCS), a multidisciplinary team led by genetic counsellors that provided advice regarding genomic testing for physicians considering GWS for their patients. Here we review the outcomes of the GCS, focusing on patients not recommended for the CAUSES Study. Methods: Demographic, clinical, and testing data were abstracted from patient charts. Logistic regression analysis was used to explore associations between demographic and clinical variables and two outcomes: the type of recommendation and referring physicians’ decisions to follow the recommendation. Results: Of 972 GCS referrals, 248 patients were not referred to the CAUSES Study. GWS (vs. a targeted test; e.g. multi-gene panel) was more likely to be recommended to physicians of patients with ID than physicians of patients without ID (OR = 2.98; 95% CI = 1.46 to 6.27; n = 149). In total, 40% of physicians who were recommended to pursue clinical genomic testing submitted an application for funding approval; 71% of applications were approved for funding. Among approved tests, 50% resulted in a diagnosis, including 33% of targeted tests and 82% of GWS tests (χ2 (1) = 5.0, p = 0.026). Conclusion: The GCS provided an effective model in which physicians can interface with genetic specialists, including genetic counsellors, to facilitate appropriate genomic test selection.
KW - Genetic counsellors
KW - Genome-wide sequencing
KW - Genomic testing recommendations
KW - Health services implementation
KW - Triage
UR - https://www.scopus.com/pages/publications/85105277332
U2 - 10.1016/j.ejmg.2020.104024
DO - 10.1016/j.ejmg.2020.104024
M3 - Article
C2 - 32798762
SN - 1769-7212
VL - 64
JO - European journal of medical genetics
JF - European journal of medical genetics
IS - 7
M1 - 104024
ER -